Trastuzumab deruxtecan
- Generic Name
- Trastuzumab deruxtecan
- Brand Names
- Enhertu
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1826843-81-5
- Unique Ingredient Identifier
- 5384HK7574
- Background
Trastuzumab deruxtecan is a HER-2 directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of metastatic, unresectable breast cancer. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuz...
- Indication
In the US, trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. It...
- Associated Conditions
- Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Adenocarcinoma, Metastatic Breast Cancer, Metastatic Breast Cancer With HER2 Positive, Unresectable Breast Cancer, Locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Locally advanced HER2-positive Gastric Adenocarcinoma, Metastatic HER2 Mutant Non-small Cell Lung Cancer, Metastatic HER2-low Breast Cancer, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic HER2-positive Gastric Adenocarcinoma, Unresectable HER2 Mutant Non-small Cell Lung Cancer, Unresectable HER2-low Breast Cancer, Unresectable HER2/Neu-positive Breast Cancer
- Associated Therapies
- -
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 866
- Registration Number
- NCT04494425
- Locations
- 🇬🇧
Research Site, Northwood, United Kingdom
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 468
- Registration Number
- NCT04482309
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 41
- Registration Number
- NCT04420598
- Locations
- 🇵🇹
Champalimaud Center for the Unknown, Lisbon, Portugal
🇵🇹Instituto Português de Oncologia do Porto Francisco Gentil, EPE (IPO Porto), Porto, Portugal
🇪🇸Hospital Universitario Virgen del Rocio, Sevilla, Spain
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 413
- Registration Number
- NCT04379596
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 63
- Registration Number
- NCT04294628
- Locations
- 🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸NYP/Weill Cornell Medical Center, New York, New York, United States
Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 186
- Registration Number
- NCT04132960
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷Centre François Baclesse, Caen, France
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
- Conditions
- Interventions
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 79
- Registration Number
- NCT04014075
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
🇺🇸USC Norris Comprehensive Cancer Center Hospital, Los Angeles, California, United States
🇺🇸UCLA Health, Santa Monica, California, United States
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 243
- Registration Number
- NCT03742102
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
- Conditions
- Interventions
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 608
- Registration Number
- NCT03523585
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸The Methodist Hospital Research Institute, Houston, Texas, United States
🇧🇪Az Groeninge, Kortrijk, Belgium
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 99
- Registration Number
- NCT03523572
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Tennessee Oncology - Sara Cannon Research Institute, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.